Thus, targeting of the BMP4–GREM1/2 axis in patients suffering from cardiac inflammation offers protection of cardiomyocyte integrity, reduction of cardiac fibrosis and, thereby, prevention of heart failure. The gene discussed is BMP4; the disease is inflammation.